IBBQ
Invesco Nasdaq Biotechnology ETF
IBBQ tracks a modified market-cap-weighted index of US biotechnology and pharmaceutical companies listed on the NASDAQ.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 116.8 M
ASSETS UNDER MGMT
19 bp
EXPENSES
Fund Basics
| Inception date | Jun 11, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| GILEAD SCIENCES INC | 9.1 % |
| AMGEN INC | 8.4 % |
| VERTEX PHARMACEUTICALS INC | 8.0 % |
| REGENERON PHARMACEUTICALS | 6.0 % |
| MODERNA, INC. | 5.6 % |
| REVOLUTION MEDICINES, INC. | 2.6 % |
| BIOGEN IDEC INC | 2.4 % |
| ILLUMINA INC | 2.3 % |
| ROYALTY PHARMA PLC CLASS A | 1.9 % |
| ROIVANT SCIENCES LTD. | 1.7 % |
Constituent Breakdown
| Number of holdings | 256 |
| Herfindahl-Hirschman Index | 254 |
| Wgt avg mkt cap (mns) | $66,818 |
| Large cap (>$10bn) | 71.2% |
| Mid cap ($2-10bn) | 18.2% |
| Small cap (<$2bn) | 6.8% |
| Developed mkts. | 94.7% |
| Emerging mkts. | 0.6% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 87.7 % |
 |
BRITAIN | 1.9 % |
 |
NETHERLANDS | 1.7 % |
 |
IRELAND | 1.4 % |
 |
CHINA | 0.9 % |
 |
GERMANY | 0.7 % |
 |
FRANCE | 0.6 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 23.8% | 44.5% | 21.6% | 21.0% | 6.5% | -- | -- | 6.2% |
| Dividend Yield | 1.1% | 1.8% | 1.4% | 1.3% | 1.1% | -- | -- | 1.1% |
| Total Returns | 24.9% | 46.3% | 22.9% | 22.4% | 7.6% | -- | -- | 7.2% | Ann. Volatility | 22.9% | 21.5% | 22.2% | 20.9% | 22.1% | -- | -- | 22.0% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.74 | 20% |
| MSCI EAFE | 0.69 | 26% |
| MSCI Emg Mkts | 0.30 | 12% |
Liquidity Measures
| Avg. volume (000) | 53 |
| ADV traded (mns) | $2 |
| Turnover | 1.6% |
| Avg. Bid/Ask (% of price) | 0.15% |
Technical Indicators
| 30d moving avg. (EMA) | $34.97 |
| Relative strength (RSI) | 56 |
| MACD/Signal | 0.37/0.20 |
| Bollinger Bands (Upper/Lower) | $36.49/$33.10 |
| Short interest (% of AUM) | 2.4% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. IBBQ |
Expenses vs. IBBQ |
ALTAR Score™ vs. IBBQ |
|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 82.4% | +25 bp | -0.4% |
| BBH | VanEck Biotech ETF | 57.6% | +16 bp | +3.5% |
| XBI | State Street SPDR S&P Biotech ETF | 42.3% | +16 bp | -2.4% |
| PBE | Invesco Biotechnology & Genome ETF | 40.1% | +40 bp | +0.4% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 38.5% | +41 bp | +6.1% |
| BBP | Virtus LifeSci Biotech Products ETF | 36.8% | +15 bp | -2.3% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 33.1% | +36 bp | +2.7% |
| BMED | Future Health ETF | 32.7% | +58 bp | +3.2% |
| WDNA | WisdomTree BioRevolution Fund | 30.1% | +26 bp | -0.5% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 29.1% | +16 bp | -2.0% |
Risk and Returns: IBBQ vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-0.4%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,388 funds in the US Equity category with an average
ALTAR Score™ of 5.7% and a standard deviation
of 2.1%. IBBQ's ALTAR Score™ is approximately -3.0 standard
deviations above the category average. This places IBBQ in the 1st percentile
among funds in the category.
Sell-Side Consensus
$42.68
PRICE TARGET
+21.6%
UPSIDE